[e-farmacos] FDA Consumer Mag. - maio/junho: campanha sobre productos "Andro"

["Vasconcelos, Pedro" <Pedro.Filho@anvisa.gov.br>]

[Sigue la nota de la FDA en la que solicita que se haga una campanha para alertar sobre los riesgos de los productos que contienen androstenediona (Andro)].

Crackdown on 'Andro' Products
Federal health officials say a crackdown on companies that manufacture,
market, or distribute products containing androstenedione, or "andro,"
is necessary due to concerns about the safety of the substance. Widely
marketed to athletes and body builders, androstenedione has been
advertised to promote muscle growth, improve muscular strength, reduce
fat, and slow aging. But androstenedione acts like a steroid once it is
metabolized by the body, and can pose similar kinds of health risks as
steroids.

"Young people, athletes and other consumers should steer clear of andro
because there are serious, substantial concerns about its safety," Health and Human Services Secretary Tommy G. Thompson said in announcing the crackdown. "Young people should understand that there are no short cuts to a stronger body and that the best way to get faster and stronger is through good diet, nutrition, and exercise."

"Athletics benefit young people's health and give them a lesson in the
value of hard work," added John P. Walters, director of the White House
Office of National Drug Control Policy. "Androstenedione and other
performance-enhancing drugs undercut these benefits by endangering our
children's healthy development and teaching them that cheating is an
acceptable component of pursuing excellence."

As part of the crackdown, the Food and Drug Administration sent letters
in March 2004 to 23 companies, asking them to stop distributing products
sold as dietary supplements that contain androstenedione and warning
them that they could face enforcement actions if they do not take
appropriate actions.

About 1 out of 40 high school seniors reported that they had used andro
in the past year, according to the HHS 2002 Monitoring the Future
survey, which tracks drug use among students. The survey, conducted by
the National Institute on Drug Abuse, also found that about 1 out of 50
10th-graders had taken andro during the previous year.

People produce androstenedione naturally during the making of testosterone and estrogen. When people consume androstenedione, it is converted to testosterone and estrogen. Scientific evidence shows that when androstenedione is taken over time and in sufficient quantities, it
may increase the risk of serious and life-threatening diseases.

Potential long-term consequences of the use of androstenedione products
in men include decreased testicle size, impotence, and the development
of female characteristics such as breast enlargement. Women who use these products may develop male characteristics such as male pattern baldness, deepening of the voice, and increased facial hair. In addition, women also may develop abnormal menstrual cycles, abnormal menstrual bleeding, and blood clots. Androstenedione use also increases the risks for breast cancer and endometrial cancer in women. Children who use these products are at risk for puberty beginning earlier and bone growth stopping prematurely.

The FDA considers dietary supplements that contain androstenedione to be
adulterated under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Supplements containing new dietary ingredients have to meet certain
requirements, and because these requirements have not been met for androstenedione, supplements containing the ingredient cannot be marketed legally.

Under the FD&C Act, the FDA is also responsible for taking action against any unsafe dietary supplement product after it reaches the market. The FDA also informed firms that it is aware of no history of use or other information establishing that a dietary supplement containing androstenedione is safe.

The National Collegiate Athletic Association, the National Football
League, and the International Olympic Committee have all banned the use
of androstenedione. The American Academy of Pediatrics, the Endocrine
Society, the American Medical Association, and other health professional
groups have cautioned against the use of certain steroids and their
precursors, like androstenedione, because of their potential long-term
adverse health consequences.

The FDA will determine whether further actions are necessary if firms
refuse to stop distribution of androstenedione products. Such actions
could include seizing illegal products as well as pursuing injunctions
or seeking criminal sanctions against people who violate the law.


Pedro Alcantara Vasconcellos Filho
ANVISA
Brasilia
(Brasil)